Fungal infections in cystic fibrosis;Infections fongiques au cours de la mucoviscidose

Archives de Pediatrie

Volumn 18, Issue SUPPL. 1, 2011, Pages

  Le Bourgeois, M ^a   Sermet, I ^a   Bailly Botuha, C ^a   Delacourt, C ^a   de Blic, J ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ARTICLE; ASPERGILLUS FUMIGATUS; EARLY DIAGNOSIS; FUNGAL COLONIZATION; FUNGAL VIRULENCE; HUMAN; LUNG FIBROSIS; MYCOSIS; PREVALENCE; SCEDOSPORIUM; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; CYSTIC FIBROSIS; EARLY DIAGNOSIS; GLUCOCORTICOIDS; HUMANS; MYCOSES; PULMONARY ASPERGILLOSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 79956154846     PISSN: 0929693X     EISSN: 1769664X     Source Type: Journal    
DOI: 10.1016/S0929-693X(11)70936-8     Document Type: Article

References (64)

1. Brown K., Rosenthal M., Bush A. Fatal invasive aspergillosis in an adolescent with cystic fibrosis. Pediatr Pulmonol 1999, 27:130-133.
2. Bonnel A.S., Quinque K., Le Roux P., et al. Aspergillose nécrosante semi-invasive chez un enfant de 14 ans atteint de mucoviscidose. Rev Mal Respir 2006, 23:343-347.
3. Shoseyov D., Brownlee K.G., Conway S.P., et al. Aspergillus bronchitis in cystic fibrosis. Chest 2006, 130:222-226.
4. Pihet M., Carrere J., Cimon B., et al. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis - -a review. Med Mycol 2009, 47:387-397.
5. Blyth M.L., Harun A., Middleton P.G., et al. Detection of occult Scedosporium species in respiratory tract specimens from patients with cystic fibrosis by use of selective media. J Clin Microbiol 2010, 48:314-316.
6. Giraud S., Pihet M., Razafimandimby B., et al. Geosmithia argillacea: an emerging pathogen in patients with cystic fibrosis. J Clin Microbiol 2010, 48:2381-2386.
7. Cimon B., Carrere J., Vinatier J.F., et al. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2000, 19:53-56.
8. Jubin V., Ranque S., Stremler Le Bel N., et al. Risk factors for Aspergillus colonization and allergic bronchopulmonary aspergillosis in children with cystic fibrosis. Pediatr Pulmonol 2010, 45:764-771.
9. Singh N., Paterson D.L. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005, 18:44-69.
10. Hinson K.F., Moon A.J., Plummer N.S. Broncho-pulmonary aspergillosis; a review and a report of eight new cases. Thorax 1952, 7:317-333.
11. Pepys J. Possible role of precipitins against aspergillus fumigatus. Am Rev Respir Dis 1964, 90:465-467.
12. Mastella G., Rainisio M., Harms H.K., et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis. Eur Respir J 2000, 16:464-471.
13. Moss R.B. Allergic bronchopulmonary aspergillosis. Clin Rev Allergy Immunol 2002, 23:87-104.
14. Geller D.E., Kaplowitz H., Light M.J., et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Chest 1999, 116:639-646.
15. Stevens D.A., Moss R.B., Kurup V.P., et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis - state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003, 37:S225-S264.
16. Maurya V., Gugnani H.C., Sarma P.U., et al. Sensitization to Aspergillus antigens and occurrence of allergic bronchopulmonary aspergillosis in patients with asthma. Chest 2005, 127:1252-1259.
17. Caballero T., Ferrer A., Diaz-Pena J.M., et al. Childhood allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 1995, 95:1044-1047.
18. Nepomuceno I.B., Esrig S., Moss R.B. Allergic bronchopulmonary aspergillosis in cystic fibrosis:role of atopy and response to itraconazole. Chest 1999, 115:364-370.
19. Ritz N., Ammann R.A., Casaulta Aebischer C., et al. Risk factors for allergic bronchopulmonary aspergillosis and sensitisation to Aspergillus fumigatus in patients with cystic fibrosis. Eur J Pediatr 2005, 164:577-582.
20. Zander D.S. Allergic bronchopulmonary aspergillosis: an overview. Arch Pathol Lab Med 2005, 129:924-928.
21. Greenberger P.A., Miller T.P., Roberts M., et al. Allergic bronchopulmonary aspergillosis in patients with and without evidence of bronchiectasis. Ann Allergy 1993, 70:333-338.
22. Vanhee L.M., Symoens F., Bouchara J.P., et al. High-resolution genotyping of Aspergillus fumigatus isolates recovered from chronically colonised patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2008, 27:1005-1007.
23. Tillie-Leblond I., Tonnel A.B. Allergic bronchopulmonary aspergillosis. Allergy 2005, 60:1004-1013.
24. Chauhan B., Santiago L., Kirschmann D.A., et al. The association of HLA-DR alleles and T cell activation with allergic bronchopulmonary aspergillosis. J Immunol 1997, 159:4072-4076.
25. Chauhan B., Santiago L., Hutcheson P.S., et al. Evidence for the involvement of two different MHC class II regions in susceptibility or protection in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2000, 106:723-729.
26. Knutsen A.P., Kariuki B., Consolino J.D., et al. IL-4 alpha chain receptor (IL-4Ralpha) polymorphisms in allergic bronchopulmonary sspergillosis. Clin Mol Allergy 2006, 4:3.
27. Marchand E., Verellen-Dumoulin C., Mairesse M., et al. Frequency of cystic fibrosis transmembrane conductance regulator gene mutations and 5T allele in patients with allergic bronchopulmonary aspergillosis. Chest 2001, 119:762-767.
28. Eaton T.E., Weiner Miller P., Garrett J.E., et al. Cystic fibrosis transmembrane conductance regulator gene mutations: do they play a role in the aetiology of allergic bronchopulmonary aspergillosis?. Clin Exp Allergy 2002, 32:756-761.
29. Miller P.W., Hamosh A., Macek M., et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis. Am J Hum Genet 1996, 59:45-51.
30. Brouard J., Knauer N., Boelle P.Y., et al. Influence of Interleukin-10 on Aspergillus fumigatus Infection in Patients with Cystic Fibrosis. J Infect Dis 2005, 191:1988-1991.
31. Saxena S., Madan T., Shah A., et al. Association of polymorphisms in the collagen region of SP-A2 with increased levels of total IgE antibodies and eosinophilia in patients with allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2003, 111:1001-1007.
32. Chu H.W., Wang J.M., Boutet M., et al. Immunohistochemical detection of GM-CSF, IL-4 and IL-5 in a murine model of allergic bronchopulmonary aspergillosis. Clin Exp Allergy 1996, 26:461-468.
33. Gibson P.G., Wark P.A., Simpson J.L., et al. Induced sputum IL-8 gene expression, neutrophil influx and MMP-9 in allergic bronchopulmonary aspergillosis. Eur Respir J 2003, 21:582-588.
34. Rosenberg M., Patterson R., Mintzer R., et al. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med 1977, 86:405-414.
35. Patterson R., Greenberger P.A., Radin R.C., et al. Allergic bronchopulmonary aspergillosis: staging as an aid to management. Ann Intern Med 1982, 96:286-291.
36. Brémont F., Rittié J.L., Rancé F., et al. Aspergillose bronchopulmonaire allergique chez l'enfant. Arch Pediatr 1999, 6(Suppl. 1):87S-93S.
37. Hemmann S., Nikolaizik W.H., Schoni M.H., et al. Differential IgE recognition of recombinant Aspergillus fumigatus allergens by cystic fibrosis patients with allergic bronchopulmonary aspergillosis or Aspergillus allergy. Eur J Immunol 1998, 28:1155-1160.
38. Kurup V.P., Banerjee B., Murali P.S., et al. Immunodominant peptide epitopes of allergen. Asp f 1 from the fungus Aspergillus fumigatus. Peptides 1998, 19:1469-1477.
39. Casaulta C., Fluckiger S., Crameri R., et al. Time course of antibody response to recombinant Aspergillus fumigatus antigens in cystic fibrosis with and without ABPA. Pediatr Allergy Immunol 2005, 16:217-225.
40. Latzin P., Hartl D., Regamey N., et al. Comparison of serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis. Eur Respir J 2008, 31:36-42.
41. Hartl D., Latzin P., Zissel G., et al. Chemokines indicate allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Am J Respir Crit Care Med 2006, 173:1370-1376.
42. Ringer S., Hipler U.C., Elsner P., et al. Potential role of the cellular allergen stimulation test (CAST) in diagnosis of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis. Pediatr Pulmonol 2007, 42:314-318.
43. Neeld D.A., Goodman L.R., Gurney J.W., et al. Computerized tomography in the evaluation of allergic bronchopulmonary aspergillosis. Am Rev Respir Dis 1990, 142:1200-1205.
44. Greenberger P.A. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002, 110:685-692.
45. Imbeault B., Cormier Y. Usefulness of inhaled high-dose corticosteroids in allergic bronchopulmonary aspergillosis. Chest 1993, 103:1614-1617.
46. Thomson J.M., Wesley A., Byrnes C.A., et al. Pulse intravenous methylprednisolone for resistant allergic bronchopulmonary aspergillosis in cystic fibrosis. Pediatr Pulmonol 2006, 41:164-170.
47. Cohen-Cymberknoh M., Blau H., Shoseyov D., et al. Intravenous monthly pulse methylprednisolone treatment for ABPA in patients with cystic fibrosis. J Cyst Fibros 2009, 8:253-257.
48. Wark P.A., Gibson P.G., Wilson A.J. Azoles for allergic bronchopulmonary aspergillosis associated with asthma. Cochrane Database Syst Rev 2003, CD001108.
49. Howard S.J., Pasqualotto A.C., Denning D.W. Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitis. Clin Microbiol Infect 2010, 16:683-688.
50. Salez F., Brichet A., Desurmont S., et al. Effects of itraconazole therapy in allergic bronchopulmonary aspergillosis. Chest 1999, 116:1665-1668.
51. Stevens D.A., Schwartz H.J., Lee J.Y., et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000, 342:756-762.
52. Conway S.P., Etherington C., Peckham D.G., et al. Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis. J Antimicrob Chemother 2004, 53:841-847.
53. Skov M., Main K.M., Sillesen I.B., et al. Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide. Eur Respir J 2002, 20:127-133.
54. Hilliard T., Edwards S., Buchdahl R., et al. Voriconazole therapy in children with cystic fibrosis. J Cyst Fibros 2005, 4:215-220.
55. Berge M., Guillemain R., Boussaud V., et al. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients. Transpl Infect Dis 2009, 11:211-219.
56. Cheng M.P., Paquette K., Lands L.C., et al. Voriconazole inhibition of vitamin A metabolism: Are adverse events increased in cystic fibrosis patients?. Pediatr Pulmonol 2010, 45:661-666.
57. Laoudi Y., Paolini J.B., Grimfeld A., et al. Nebulised corticosteroid and amphotericin B: an alternative treatment for ABPA?. Eur Respir J 2008, 31:908-909.
58. Hayes D., Murphy B.S., Lynch J.E., et al. Aerosolized amphotericin for the treatment of allergic bronchopulmonary aspergillosis. Pediatr Pulmonol 2010, 45:1145-1148.
59. Zirbes J.M., Milla C.E. Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatr Pulmonol 2008, 43:607-610.
60. van der Ent C.K., Hoekstra H., Rijkers G.T. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 2007, 62:276-277.
61. Kanu A., Patel K. Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab). Pediatr Pulmonol 2008, 43:1249-1251.
62. Brinkmann F., Schwerk N., Hansen G., et al. Steroid dependency despite omalizumab treatment of ABPA in cystic fibrosis. Allergy 2010, 65:134-135.
63. Lebecque P, Leonard A, Pilette C. Omalizumab for treatment of ABPA exacerbations in CF patients. Pediatr Pulmonol 2009;44:516. Erratum in Pediatr Pulmonol 2009;44:943-4.
64. Greenberger P.A., Patterson R. Diagnosis and management of allergic bronchopulmonary aspergillosis. Ann Allergy 1986, 56:444-448.